Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2008-04-22
2008-04-22
Allen, Marianne P. (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C530S398000, C530S399000, C530S402000, C530S403000, C514S012200, C514S013800
Reexamination Certificate
active
07361349
ABSTRACT:
A peptide that comprises a modified tandem GnRH decapeptide sequence which allows for a testosterone level that is essentially nondetectable after vaccination with the peptide in a suitable dosage and/or allows for an immunogenic response that allows for the effective discrimination between GnRH-I and GnRH-II and a method for the immunocastration of pigs.
REFERENCES:
patent: 4075191 (1978-02-01), Beddell et al.
patent: 4608251 (1986-08-01), Mia
patent: 4758552 (1988-07-01), Gulyas et al.
patent: 5484592 (1996-01-01), Meloen et al.
patent: 5573767 (1996-11-01), Dufour et al.
patent: 5723129 (1998-03-01), Potter et al.
patent: 5885966 (1999-03-01), Meloen et al.
patent: 6284733 (2001-09-01), Meloen et al.
patent: 6761890 (2004-07-01), Meloen et al.
patent: RE39048 (2006-03-01), Meloen et al.
patent: 2196969 (1988-05-01), None
patent: 2228262 (1990-08-01), None
patent: 2282813 (1995-04-01), None
patent: WO 88/05308 (1988-07-01), None
patent: WO 90/11298 (1990-10-01), None
patent: WO 96/40755 (1996-12-01), None
Oonk et al., New GnRH-like peptide construct to optimize efficient immunocastration of male pigs by immunoneutralization of GnRH, Vaccine, 1998, pp. 1074-1082, vol. 16, No. 11/12, Elsevier Science Ltd., Great Britain.
Turkstra et al., The role of the individual amino acids of a GaRH-tandem-dimer peptide used as an antigen for immunocastration of male piglets determined with systematic alanine replacements, Vaccine, 2002, pp. 406-412, vol. 20.
Alston-Mills et al., Production of Monoclonal Antibodies Against Avian LHRH-I. In Vitro Cellular and Developmental Biology, 1989, pp. 934-938, vol. 25, No. 10.
Wells, Additivity of Mutational Effects in Proteins, Biochemistry, 1990, pp. 8509-8517, vol. 29, No. 37.
Daniel et al., Mapping of Linear Antigenic Sites on the . . . A Combination of Nine Prediction Algorithms Fail to Identify Relevant Epitopes and Peptide Immunogenicity is Drastically Influenced by Nature of Protein Carrier, Virology, 1994, pp. 540-549, vol. 202.
Clarke et al., Neonatal Immunization against Gonadotropin-Releasing Hormone(GnRH) Results in Diminished GnRH Secretion in Adulthood, Endocrinology, 1998, pp. 2007-2014, vol. 139, No. 4.
Lescheid et al., A second Form of Gonadotropin-Releasing Hormone (GnRH) with Characteristics of Chicken GnRH-II Is Present in the Primate Brain, Endocrinology, 1997, pp. 5618-5629, vol. 138. No. 12.
White et al., Second gene for gonadotropin-releasing hormone in humans, Proc. Natl. Acad. Sci., Jan. 1998, pp. 305-309, vol. 95.
Ladd et al., Development of an antifertility vaccine for pets based on active immunization against luteinizing hormone-releasing hormone, Abstract, Biology Reproduction, 1994, pp. 1076-1083, vol. 51.
Oikawa et al., Expression of gonadotropin-releasing hormone and prothymosin-alpha messenger ribonucleic acid in the ovary, Abstract, Endocrinology, 1990, pp. 2350-2356, vol. 127.
Meloen et al., “Efficient Immunocastration of Male Piglets by Immunoneutralization of GnRH Using a New GnRH-Like Peptide”, vol. 12, No. 8, Jan. 1994, pp. 741-746.
Burgess et al., “Possible Dissociation of the Heparin-Binding and Mitogenic Activities of Heparin-Binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-Binding Activities by Site-Directed Mutagenesis of a Single Lysine Residue”, 111:2129-2138, The Journal of Cell Biology, Nov. 1990.
Kumar et al., “Amino Acid Variations at a Single Residue in an Autoimmune Peptide Profoundly Affect its Properties: T-cell Activation, Major Histocompatibility Complex Binding, and Ability to Block Experimental Allergic Encephalomyelitis”, 87:1337-1341. Proc. Natl. Acad. Sci. USA, Feb. 1990.
Lazar et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities”, 8(3):1247-52, Molecular and Cellular Biology, Mar. 1988.
Salgaller et al. “Generation of Specific Anti-Melanoma Reactivity by Stimulation of Human Tumor-Infiltrating Lymphocytes with MAGE-1 Synthetic Peptide”, 39:105-116. Cancer Immunol. 1994.
Meloen Robert Hans
Oonk Hendrica Berendina
Allen Marianne P.
DeBerry Regina M
Pepscan Systems B.V.
TraskBritt
LandOfFree
Peptide, immunogenic composition and vaccine or medical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide, immunogenic composition and vaccine or medical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide, immunogenic composition and vaccine or medical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2789127